|
On 27th, October, 12 projects signed contract with SIMZ, including Covance R & D center, Analogic Medical Device, etc. It indicated tangible achievements of SIMZ in building Shanghai’s bio-medical industry base.
In May of 2009, Nanhui District was incorporated into Pudong District. In July of 2009, “Activities to develop bio-medical industry in Shanghai” was released, in which, SIMZ and ZhangJiang hi-tech park was united as Pudong Zhangjiang-Zhoukang core R & D zone and SIMZ was listed important industry base for development of bio-medical industry in Shanghai. In the same month, Shanghai Development and Reform Commission, Science & Technology Commission released “Several Regulations to promote Shanghai Bio-medical Industry Development”, to tailor-make 39 supportive policies for Shanghai bio-medical industry.
As the key zone of developing modern manufacturing and service industry, Shanghai International Medical Zone will take the historical opportunity, make use of its geographical advantage of neighboring Zhangjiang Hi-tech Park and the Airport, so as to develop healthcare service industry as well as high-end medical device industry and medicine with Chinese intellectual property rights. SIMZ will spread its influence to neighboring districts, and try to become the medical center of Asia in 5 years.
Besides the 12 signing project, 20 projects including Shanghai Pharmaceutical Group and Fuxing Medical are very hopeful to settle in SIMZ and their total investment will be about 2.5 billion yuan.
The 12 projects covered a total area of 455 mu, the total investment converted to RMB is 2.35 billion yuan. Among the 12 projects, there are 6 bio-medicine (R &D, Production, Sales, CRO) projects, 5 medical device projects. After coalition with Zhangjiang Hi-tech Park, the master plan of Zhangjiang R & D and SIMZ production come into effect. After the 12 projects start operation, the annual output will reach 8.42 billion yuan and will become an impetus for Pudong’s bio-medical industry.
Because of the above positive factors, SIMZ has witnessed fabulous opportunity of development. From January to September, industry output has increased by 22.8% compared to same period of last year, and the investment in fixed assets has increased by 50.6% compared to same period of last year.
* Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. It offers drug development solutions from preclinical through commercialization.
* Analogic (NASDAQ: ALOG) is a growth-oriented, high-technology, signal- and image-processing company, providing products and services to original equipment manufacturers (OEMs) and end users worldwide. It is recognized for continuing invention and innovation in computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, digital radiography (DR), patient monitoring, and aviation security, with growing capabilities in molecular imaging and advanced motion controls.
|
